person · Reporting owner

Grossman William

Disclosed activity across 4 companies

Tapewire entity: 37103
SEC CIK: 0001730229

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcus Biosciences, Inc.RCUS · Entity 4104	Chief Medical Officer	June 16, 2021	June 21, 2021
BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976	Sr. VP, Chief Medical Officer	February 05, 2019	February 07, 2019
enGene Therapeutics Inc.ENGN · Entity 6638	Director · Interim Chief Medical Officer	September 22, 2026	September 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date June 16, 2021 · Filed June 21, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,741	Reported balance After 2021-06-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-06-16 · Sale · Disposed 3,047 · Balance 24,741 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Includes 1,071 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan
Common StockSEC Table I · non-derivative	Direct	24,614	Reported balance After 2021-06-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-06-16 · Sale · Disposed 127 · Balance 24,614 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	20,723	Reported balance After 2021-06-17 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2021-06-17 · Sale · Disposed 3,891 · Balance 20,723 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Includes 1,071 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

BELLICUM PHARMACEUTICALS, INC

Report date February 05, 2019 · Filed February 07, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,874	Reported balance After 2019-02-05 transaction · row 1 1 source row Row 1 · 2019-02-05 · Tax withholding · Disposed 3,126 · Balance 26,874 F1: Represents the number of shares withheld by and surrendered to the Issuer on February 5, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to the reporting person on February 5, 2018 for 30,000 shares, which vest in four equal annual installments on each anniversary of February 5, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares withheld by and surrendered to the Issuer on February 5, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to the reporting person on February 5, 2018 for 30,000 shares, which vest in four equal annual installments on each anniversary of February 5, 2018.

enGene Therapeutics Inc.

Report date September 22, 2026 · Filed September 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	5,102	Reported balance After 2026-09-22 transaction · row 1 1 source row Row 1 · 2026-09-22 · Purchase · Acquired 5,102 · Balance 5,102

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-16	Direct	Reported balance After 2026-04-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 66,660 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F1: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22	Direct	Reported balance After 2026-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01	Direct	Reported balance After 2026-04-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F7: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F9: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5: The options are fully vested.

F6: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

F7: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F8: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F9: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 22, 2026 Filed Sep 24, 2026 20:40 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	5,102	$1.97	$10,050.94	Disclosure SEC source: 0001552781-26-000501 · ownership.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,102 Read SEC document
June 16, 2026 Filed Jun 17, 2026 21:40 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0000929638-26-002260 · form4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2036-06-16 F2 · derivative.exercise_date: This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company. Read SEC document
June 16, 2026 Filed Jun 17, 2026 21:40 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	GrantStock Option (Right to Buy) · Derivative	31,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0000929638-26-002260 · form4.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Shares · 31,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:31 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001730229-26-000001 · form4-04232026_080449.xml · derivative · entry 4 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F9 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:31 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	22,500	Not disclosed Strike: $7.01	Not disclosed	Disclosure SEC source: 0001730229-26-000001 · form4-04232026_080449.xml · derivative · entry 3 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2035-06-01 F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:31 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	32,335	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001730229-26-000001 · form4-04232026_080449.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:31 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	66,660	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001730229-26-000001 · form4-04232026_080449.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,660 shares Expires 2034-01-16 F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F1 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 22:59 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	32,335	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001730229-25-000004 · form4-11072025_101140.xml · derivative · entry 4 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,335 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 22:59 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	32,335	$0.00 Strike: $13.87	$0.00	Disclosure SEC source: 0001730229-25-000004 · form4-11072025_101140.xml · derivative · entry 3 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 22:59 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	66,660	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001730229-25-000004 · form4-11072025_101140.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,660 Underlying: Common Stock · 66,660 shares Expires 2034-01-16 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 22:59 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	66,660	$0.00 Strike: $13.81	$0.00	Disclosure SEC source: 0001730229-25-000004 · form4-11072025_101140.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,660 shares Expires 2034-01-16 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 08, 2025 Filed Jul 10, 2025 20:06 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	GrantStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $3.83	$0.00	Disclosure SEC source: 0000929638-25-002556 · form4.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-07-08 F1 · derivative.exercise_date: This option vests at 1/3 on each of the first, second and third anniversaries of Dr. Grossman's date of appointment to the Board, which was July 8, 2025. Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:54 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantRestricted Stock Unit (RSU) · Derivative	15,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-25-015631 · form4-06042025_090613.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.. Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:54 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	22,500	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001415889-25-015631 · form4-06042025_090613.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-01 F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Read SEC document
May 23, 2024 Filed May 28, 2024 22:44 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	32,335	$0.00 Strike: $13.87	$0.00	Disclosure SEC source: 0001415889-24-014729 · form4-05282024_100533.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,335 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 17, 2024 Filed Jan 19, 2024 22:22 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	66,660	$0.00 Strike: $13.81	$0.00	Disclosure SEC source: 0001209191-24-001950 · doc4.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,660 Underlying: Common Stock · 66,660 shares Expires 2034-01-16 F1 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:48 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	3,891	$23.68	$92,138.88	Disclosure SEC source: 0001209191-21-042074 · doc4.xml · nonDerivative · entry 3 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,723 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:48 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	127	$24.77	$3,145.79	Disclosure SEC source: 0001209191-21-042074 · doc4.xml · nonDerivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,614 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:48 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	3,047	$24.13	$73,524.11	Disclosure SEC source: 0001209191-21-042074 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,741 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 1,071 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan Read SEC document
April 23, 2021 Filed Apr 26, 2021 20:14 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	4,133	$31.37	$129,652.21	Disclosure SEC source: 0001179110-21-004603 · edgar.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,717 F1 · shares: Shares sold in a private transaction to Dr. Yasunori Kaneko, a director of Arcus Biosciences, Inc. The shares, representing approximately 1.6% of the total shares either owned or that may be acquired by Dr. Grossman upon exercise of options that are vested and exercisable, were sold by Dr. Grossman as part of his tax plan. Read SEC document
March 16, 2021 Filed Mar 18, 2021 20:37 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	2,127	$35.03	$74,508.60	Disclosure SEC source: 0001209191-21-021772 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.98 to $35.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:11 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (right to buy) · Derivative	112,500	$0.00 Strike: $36.73	$0.00	Disclosure SEC source: 0001209191-21-004265 · doc4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:11 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	18,750	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004265 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,477 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document
December 16, 2020 Filed Dec 18, 2020 21:51 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	SaleCommon Stock	2,117	$31.35	$66,367.95	Disclosure SEC source: 0001209191-20-064444 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,727 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. F2 · balance_after: Includes 992 shares purchased on 5/29/2020 and 1,002 shares purchased on 11/30/2020 through the Company's Employee Stock Purchase Plan. Read SEC document
October 02, 2020 Filed Oct 5, 2020 21:02 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (right to buy) · Derivative	100,000	$17.00 Strike: $17.00	$1,700,000.00	Disclosure SEC source: 0001209191-20-053710 · doc4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-01 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document
October 02, 2020 Filed Oct 5, 2020 21:02 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	100,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-053710 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 F1 · shares: Represents the grant of restricted stock units that vest in quarterly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document
July 31, 2020 Filed Aug 4, 2020 22:13 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	PurchaseCommon Stock	100	$19.68	$1,967.56	Disclosure SEC source: 0001209191-20-044798 · doc4.xml · nonDerivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Read SEC document
July 31, 2020 Filed Aug 4, 2020 22:13 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	PurchaseCommon Stock	100	$19.77	$1,977.00	Disclosure SEC source: 0001209191-20-044798 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:26 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034978 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,400 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document
January 17, 2020 Filed Jan 22, 2020 15:44 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (right to buy) · Derivative	140,000	$0.00 Strike: $10.23	$0.00	Disclosure SEC source: 0001209191-20-004398 · doc4.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document
October 14, 2019 Filed Oct 15, 2019 22:15 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	PurchaseCommon Stock	300	$8.00	$2,400.00	Disclosure SEC source: 0001209191-19-053207 · doc4.xml · nonDerivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Read SEC document
October 10, 2019 Filed Oct 15, 2019 22:15 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	PurchaseCommon Stock	100	$8.00	$800.00	Disclosure SEC source: 0001209191-19-053207 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document
April 29, 2019 Filed May 1, 2019 20:16 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (right to buy) · Derivative	400,000	$0.00 Strike: $10.49	$0.00	Disclosure SEC source: 0001209191-19-026755 · doc4.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-04-28 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after April 29, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document
February 05, 2019 Filed Feb 7, 2019 16:02 UTC	BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976	Tax withholdingCommon Stock	3,126	$3.48	$10,878.48	Disclosure SEC source: 0001358403-19-000026 · wf-form4_154957330959098.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,874 F1 · kind: Represents the number of shares withheld by and surrendered to the Issuer on February 5, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to the reporting person on February 5, 2018 for 30,000 shares, which vest in four equal annual installments on each anniversary of February 5, 2018. Read SEC document
February 01, 2019 Filed Feb 5, 2019 16:09 UTC	BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976	GrantStock Option (right to buy) · Derivative	82,500	$0.00 Strike: $3.35	$0.00	Disclosure SEC source: 0001358403-19-000019 · wf-form4_154940092828630.xml · derivative · entry 1 Grossman William · CIK 0001730229 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2029-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
February 05, 2018 Filed Feb 7, 2018 18:06 UTC	BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976	GrantEmployee Stock Option (right to buy) · Derivative	175,000	$0.00 Strike: $5.61	$0.00	Disclosure SEC source: 0001209191-18-008213 · doc4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-02-04 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 5, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
February 05, 2018 Filed Feb 7, 2018 18:06 UTC	BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-008213 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments on each anniversary of February 5, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.